Lipid abnormalities in renal disease

Virchow R. A more precise account of fatty metamorphosis. In: Virchow R , ed. Cellular Pathology. 2nd edition. London: Churchill, 1960: 342–66

Wheeler DC , Bernard DB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences and treatment. Am J Kidney Dis 1994; 23: 331–46

Attman P-O , Samuelsson O , Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573–92

Wheeler DC. Should hyperlipidaemia in dialysis patients be treated? Nephrol Dial Transplant 1997; 12: 19–21

Dimény E , Fellström B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant 1997; 12: 21–24

Wheeler DC. Lipids—What is the evidence for their role in progressive renal disease? Nephrol Dial Transplant 1995; 10: 14–16

Deckelbaum RJ. Structure and composition of human plasma lipoproteins. In: Olsson AG , ed. Atherosclerosis: Biology and Clinical Science. Edinburgh: Churchill Livingstone, 1987: 251–55

Mahley RW , Innerarity TL , Rall SC Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277–94

Steyrer E , Durovic S , Frank S The role of lecithin: cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94: 2330–40

Schanu AM , Fless GM. Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709–15

Newmark SR , Anderson CF , Donadio JV Lipoprotein profiles in adult nephrotics. Mayo Clin Proc 1975; 50: 359–64

Joven J , Villabona C , Vilella E Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323: 579–84

Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–83

Yamauchi A , Fukuhara Y , Yamamoto S Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992; 263: C397–404

Warwick GL , Packard CJ , Demant T Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991; 40: 129–38

Vega G , Toto RD , Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995; 47: 579–86

Davies RW , Staprans I , Hutchison FN Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990; 86: 600–5

Rajman I , Harper L , McPake D Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281–7

Gruber KK , Haffner SM , Tuttle KR. Increased Lp(a) concentrations in chronic renal failure [Abstract]. J Am Soc Nephrol 1992; 3: 333

Brown WV , Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972; 46: 375–82

Cheung AK , Parker CJ , Ren K Increased lipase inhibition in uremia; Identification of pre-β HDL as a major inhibitor in normal and uremic plasma. Kidney Int 1996; 49: 1360–71

Wheeler DC. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996; 50(suppl. 56):S41–6

Avram MM , Goldswasser P , Burrell DE The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20: 324–35

Blankestijn PJ , Vos PF , Rabelink TJ High-flux dialysis membranes improve lipid profile in chronic haemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–8

Dimény E , Wahlberg J , Lithell H Hyperlipidaemia in renal transplantation-risk factor for long term graft outcome. Eur J Clin Invest 1995; 25: 574–83

Attman P-O , Alaupovic P , Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987; 32: 368–75

Cressman MD , Heyka RJ , Paganini EP Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–82

Keane WF , Kasiske BL , O'Donnell MP The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991; 17: 38–42

Moorhead JF , Wheeler DC , Varghese Z. Glomerular structures and lipids in progressive renal disease. Am J Med 1989; 87(suppl 5N):12N–20N

Neugarten J , Schlondorff D. Lipoprotein interactions with glomerular cells and matrix. Contemp Issues Nephrol 1991; 24: 173–206

Isoniemi H , Nurminen M , Tikkanen MJ Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57: 68–72

Fellström BC , Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev 1993; 134: 83–98.

Sanfelippo ML , Swenson RS , Reaven GM. Reduction of plasma triglylcerides by diet in subjects with chronic renal failure. Kidney Int 1977; 11: 54–61

Massy ZA , Ma JZ , Louis TA , Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188–98

Wheeler DC. Statins and the kidney. Curr Opin Nephrol Hypertens 1998; 7: 579–84

Vaughan CJ , Murphy MB , Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–82

O'Donnell MP , Kasiske BL , Kim Y Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83–7

Katznelson S , Wilkinson AH , Kobashigawa JA The effect of pravastatin on acute rejection after kidney transplantation. A pilot study. Transplantation 1996; 61: 1469–74